The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)- Horizon Discovery Group plc

4 May 2018 10:03

RNS Number : 1635N
JPMorgan Securities Plc
04 May 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Horizon Discovery Group plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Corporate Broker and Financial Advisor to Abcam plc

(d) Date dealing undertaken:

03 May 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, Abcam plc

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received (GBP)

 

Lowest price per unit paid/received (GBP)

 

Ordinary Shares

Purchases

 

Sales

100,398

 

79,809

1.9600

 

1.9450

1.8801

 

1.9000

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBP)

Ordinary Shares

Equity Swaps

 

Long

 

Short

77,829

 

218

 6,016

 65,144

 7,874

 4,437

 10,390

 4,339

1.9000

 

1.8801

1.9000

1.9077

1.9214

1.9272

1.9337

1.9578

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBP)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit (GBP)

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit (GBP)

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

(GBP)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

04 May 2018

Contact name:

Alwyn Basch

Telephone number:

020 7742 7407

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERFKQDKCBKKKPK
Date   Source Headline
16th Jan 20177:00 amRNSHorizon broadens gene editing capabilities
13th Jan 20177:00 amRNSAdditional Listing
6th Jan 20171:24 pmRNSAdditional Listing
29th Dec 201610:28 amRNSHolding(s) in Company
15th Dec 20167:00 amRNSAdditional Listing
2nd Dec 201611:30 amRNSDirector/PDMR Shareholding
2nd Dec 201610:00 amRNSDirector Dealings
16th Nov 20167:00 amRNSHZD Enters Chinese Clinical Diagnostics Market
14th Nov 20167:00 amRNSAdditional Listing
9th Nov 20167:00 amRNSOEM Agreement with CareDx for Reference Standards
1st Nov 20167:00 amRNSProgress Update: Molecular Screening Platform
31st Oct 201612:36 pmRNSAdditional Listing
19th Oct 20167:00 amRNSLicensing Agreement: Biomanufacturing Cell Lines
10th Oct 20167:00 amRNSAdditional Listing
30th Sep 20163:25 pmRNSHolding(s) in Company
30th Sep 20167:00 amRNSAdditional Listing
23rd Sep 20161:46 pmRNSHolding(s) in Company
21st Sep 20165:28 pmRNSHolding(s) in Company
20th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
13th Sep 20169:04 amRNSHolding(s) in Company
13th Sep 20167:00 amRNSBiomanufacturing Cell Lines Licensed to CPI, NIBRT
12th Sep 201611:04 amRNSHolding(s) in Company
7th Sep 201612:19 pmRNSHolding(s) in Company
7th Sep 20167:02 amRNSNotice of Interim Results
7th Sep 20167:00 amRNSAdditional Listing
6th Sep 201612:31 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSCRISPR Collaboration with Fulcrum Therapeutics
1st Sep 20167:00 amRNSHZD and Ventana Sign Reference Standards Agreement
18th Aug 20167:00 amRNSAdditional Listing
16th Aug 20164:09 pmRNSHolding(s) in Company
3rd Aug 20163:26 pmRNSHolding(s) in Company
29th Jul 20163:31 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHorizon Discovery Group Issue of Equity
26th Jul 201610:47 amRNSAdditional Listing
21st Jul 20169:11 amRNSAdditional Listing
13th Jul 20161:20 pmRNSHoldings in Company
7th Jul 20169:17 amRNSHoldings in Company
4th Jul 20164:33 pmRNSHoldings in Company
29th Jun 20164:01 pmRNSAdditional Listing
28th Jun 20167:00 amRNSAdditional Listing
24th Jun 201611:20 amRNSResult of AGM
9th Jun 20162:21 pmRNSGrant of Options
7th Jun 20165:19 pmRNSAnnual Report and Notice of Annual General Meeting
3rd Jun 20167:00 amRNSAdditional Listing
1st Jun 20167:00 amRNSReference Standards used in QIAGEN NGS System
12th May 20167:00 amRNSOEM Agreements with Market Leading NGS Company
11th May 20167:00 amRNSAdditional Listing
28th Apr 20167:45 amRNSAdditional Listing
26th Apr 20167:35 amRNSPreliminary Results for the Year Ended 31 Dec 2015
19th Apr 20167:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.